Filing Flows › Kymera Therapeutics (KYMR) › Q4 2024
Kymera Therapeutics (KYMR) Q4 2024 earnings results (fourth quarter 2024)
10-K filed Feb 27, 2025
Kymera Therapeutics (KYMR) reported revenue of $7.4M for the fourth quarter 2024 (Q4 2024), -85% from a year earlier and +98% from the quarter before.
Kymera Therapeutics, Q4 2024: revenue $7.4M (-85% year over year), net loss $70.8M, operating cash flow −$61.8M. The chart follows the revenue to costs, profit and cash.
| Q4 2024 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $7.4M | +98% | -85% |
| Operating profit | −$80.8M | — | — |
| Net earnings | −$70.8M | — | — |
| Operating cash flow | −$61.8M | — | — |
What changed
Revenue was $7.4M in Q4 2024, down 85% year over year and up 98% from the previous quarter.
Operating costs exceeded revenue by $80.8M, an operating margin of -1092.2%. Total costs grew 31% against a revenue fall of 85%. The quarter ended with a net loss of $70.8M, wider than the previous quarter's $62.5M loss.
Operating cash flow was −$61.8M. Non-cash charges added back $2.0M of depreciation and amortization and $13.8M of share-based compensation. Working capital and other items used $6.8M. Capital expenditures of $936K exceeded it, leaving free cash flow of −$62.7M.
Questions
What was Kymera Therapeutics' revenue in the fourth quarter 2024?
Kymera Therapeutics (KYMR) reported revenue of $7.4M for the fourth quarter 2024 (Q4 2024), -85% from a year earlier and +98% from the quarter before.